Data to be presented at the 40th Annual Society for Immunotherapy of Cancer (SITC) Meeting on November 7th and 9th BOSTON and LONDON – November 4, 2025 – …
Akari Therapeutics Announces Formation of Scientific Advisory Board and Inaugural Appointment of Renowned Medical Oncologist, Sara A. Hurvitz, MD, FACP
Dr. Hurvitz is an international expert in oncology and a recognized clinical research leader with extensive experience leading clinical trials spanning all …
Akari Therapeutics Announces Launch of CEO Corner Platform
CEO Corner segments to provide added perspective to press releases, corporate developments and pipeline progress Provides interested parties with the ability …
[Read more...] about Akari Therapeutics Announces Launch of CEO Corner Platform
Akari Therapeutics Announces $2.5Million Registered Direct Offering
BOSTON and LONDON – October 15, 2025 – Akari Therapeutics, Plc (Nasdaq: AKTX) (the “Company”), an oncology biotechnology company …
[Read more...] about Akari Therapeutics Announces $2.5Million Registered Direct Offering
Akari Therapeutics Files Two NewPatents for Immuno-Oncology Mode of Action for Novel ADC Platform Utilizing Spliceosome Modulating Payload PH1
BOSTON and LONDON – October 9, 2025 – Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing novel payload antibody drug …
